ADCendo has secured a loan amount to advance its novel antibody-drug conjugates (ADCs) that are being developed to treat cancers.

The company secured the $1.48m convertible loan as part of the BioInnovation Institute (BII) Creation House programme.

ADCendo is a spin-out from the Finsen Laboratory of Rigshospitalet and the University of Copenhagen.

The company aimed to develop ADCs as anti-cancer drugs, which target the receptor, uPARAP.

This approach is useful for targeted therapy in osteosarcoma, soft-tissue sarcoma triple-negative breast cancer and glioblastoma multiforme (GBM).

The company also expects that using this therapy along with uPARAP-positive stromal cells could potentially treat more common carcinomas such as colon, prostate, renal, breast, pancreatic and ovarian cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ADCendo CSO Niels Behrendt said: “Based on our early results obtained at the Finsen Laboratory, we were granted a pre-seed grant from Novo Holdings enabling us to make significant improvements to the overall performance of our early ADC candidates.

“Our results have been very well received by our international ADC network and with the expanded access to BII, as  well as the additional financial support, we are looking forward to furthering the development of our clinical candidate.”

ADCendo is also working on its clinical trial plans for the treatment of metastatic soft tissue sarcoma.

Additionally, the company is working on a drug to substitute the STS treatment drug Lartruvo, which was withdrawn earlier this year as it had failed in a confirmatory phase III study.